Specifically, we found that additional SYK inhibition, both that of PRT062607 and the clinically investigated SYK inhibitor, entospletinib, augments the anti‐leukaemic activity of midostaurin and other FLT3 inhibitors regardless of their respective SYK‐targeting activity in our cell line models of mutant CBL‐positive leukaemia as well as mutant FLT3/mutant CBL‐positive MOLM14 cells. Here, SYK is linked to leukemia.